Research and prospect of peptides for use in obesity treatment (Review)

被引:7
作者
Gao, Yao [1 ]
Yuan, Xuewen [1 ]
Zhu, Ziyang [1 ]
Wang, Dandan [1 ]
Liu, Qianqi [1 ]
Gu, Wei [1 ]
机构
[1] Nanjing Med Univ, Childrens Hosp, Dept Endocrinol, 72 Guangzhou Rd, Nanjing 210008, Jiangsu, Peoples R China
关键词
obesity; peptidomics; peptides; treatment; metabolic diseases; BROWN ADIPOSE-TISSUE; GLUCAGON-LIKE PEPTIDE-1; INHIBITS WEIGHT-GAIN; HIGH-FAT DIET; NEUROPEPTIDE-Y; ENERGY-BALANCE; FOOD-INTAKE; WHITE FAT; INTRACELLULAR PEPTIDES; PROTEIN-DEGRADATION;
D O I
10.3892/etm.2020.9364
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Obesity and its related diseases, such as type 2 diabetes, hypertension and cardiovascular disease, are steadily increasing worldwide. Over the past few decades, numerous studies have focused on the differentiation and function of brown and beige fat, providing evidence for their therapeutic potential in treating obesity. However, no specific novel drug has been developed to treat obesity in this way. Peptides are a class of chemically active substances, which are linked together by amino acids using peptide bonds. They have specific physiological activities, including browning of white fat. As signal molecules regulated by the neuroendocrine system, the role of polypeptides, such as neuropeptide Y, brain-gut peptide and glucagon-like peptide in obesity and its related complications has been revealed. Notably, with the rapid development of peptidomics, peptide drugs have been widely used in the prevention and treatment of metabolic diseases, due to their short half-life, small apparent distribution volume, low toxicity and low side effects. The present review summarizes the progress and the new trend of peptide research, which may provide novel targets for the prevention and treatment of obesity.
引用
收藏
页数:10
相关论文
共 141 条
[1]  
Ahrens VM, 2012, FUTURE MED CHEM, V4, P1567, DOI [10.4155/FMC.12.76, 10.4155/fmc.12.76]
[2]   MicroRNA regulatory networks in human adipose tissue and obesity [J].
Arner, Peter ;
Kulyte, Agne .
NATURE REVIEWS ENDOCRINOLOGY, 2015, 11 (05) :276-288
[3]   Leptin, gut, and food intake [J].
Attele, AS ;
Shi, ZQ ;
Yuan, CS .
BIOCHEMICAL PHARMACOLOGY, 2002, 63 (09) :1579-1583
[4]   Three new players in energy regulation: Preptin, adropin and irisin [J].
Aydin, Suleyman .
PEPTIDES, 2014, 56 :94-110
[5]  
Azkargorta M, 2018, METHODS MOL BIOL, V1719, P59, DOI 10.1007/978-1-4939-7537-2_4
[6]   Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure [J].
Baggio, LL ;
Huang, QL ;
Brown, TJ ;
Drucker, DJ .
GASTROENTEROLOGY, 2004, 127 (02) :546-558
[7]   Intermedin (adrenomedullin-2): a novel counter-regulatory peptide in the cardiovascular and renal systems [J].
Bell, D. ;
McDermott, B. J. .
BRITISH JOURNAL OF PHARMACOLOGY, 2008, 153 :S247-S262
[8]   Identification of intracellular peptides in rat adipose tissue: Insights into insulin resistance [J].
Berti, Denise A. ;
Russo, Lilian C. ;
Castro, Leandro M. ;
Cruz, Lilian ;
Gozzo, Fabio C. ;
Heimann, Joel C. ;
Lima, Fabio B. ;
Oliveira, Ariclecio C. ;
Andreotti, Sandra ;
Prada, Patricia O. ;
Heimann, Andrea S. ;
Ferro, Emer S. .
PROTEOMICS, 2012, 12 (17) :2668-2681
[9]   Progress and challenges in anti-obesity pharmacotherapy [J].
Bessesen, Daniel H. ;
Van Gaal, Luc F. .
LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (03) :237-248
[10]   Targeted Protein Degradation by Small Molecules [J].
Bondeson, Daniel P. ;
Crews, Craig M. .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 57, 2017, 57 :107-123